# Atomoxetine - First non-stimulant ADHD medication
# Approved in US, China, EU, Japan

id: "atomoxetine"

brandNames:
  US: ["Strattera"]
  CN: ["择思达 (Strattera)"]
  EU: ["Strattera", "Atomoxetine generics"]
  JP: ["ストラテラ (Strattera)"]
  UK: ["Strattera"]
  AU: ["Strattera"]
  CA: ["Strattera"]

genericName:
  en: "atomoxetine hydrochloride"
  zh: "盐酸托莫西汀"
  ja: "アトモキセチン塩酸塩"

manufacturers:
  - name: "Eli Lilly"
    region: "US"
    product: "Strattera"
  - name: "礼来 (Eli Lilly China)"
    region: "CN"
    product: "择思达"
  - name: "日本イーライリリー"
    region: "JP"
    product: "ストラテラ"

# Classification
drugClass: "non-stimulant"

drugClassLabel:
  en: "Non-Stimulant"
  zh: "非兴奋剂"
  ja: "非中枢刺激薬"

category: "SNRI"

categoryLabel:
  en: "Selective Norepinephrine Reuptake Inhibitor"
  zh: "选择性去甲肾上腺素再摄取抑制剂"
  ja: "選択的ノルエピネフリン再取り込み阻害薬"

controlledSubstance: false

schedule:
  US: "Not scheduled"
  CN: "Not scheduled (prescription only)"
  EU: "Not scheduled"
  JP: "Not scheduled"
  UK: "Not scheduled"

# Mechanism
activeIngredient:
  en: "atomoxetine hydrochloride"
  zh: "盐酸托莫西汀"
  ja: "アトモキセチン塩酸塩"

mechanismOfAction:
  en: "Selectively inhibits the presynaptic norepinephrine transporter, increasing norepinephrine levels in the prefrontal cortex. Unlike stimulants, does not significantly affect dopamine in the nucleus accumbens, resulting in lower abuse potential."
  zh: "选择性抑制突触前去甲肾上腺素转运体，增加前额叶皮层中去甲肾上腺素的水平。与兴奋剂不同，不会显著影响伏隔核中的多巴胺，因此滥用风险较低。"
  ja: "シナプス前のノルエピネフリントランスポーターを選択的に阻害し、前頭前皮質のノルエピネフリン濃度を上昇させます。刺激薬とは異なり、側坐核のドーパミンに大きな影響を与えないため、乱用の可能性が低くなります。"

neurotransmittersAffected:
  - norepinephrine

# Dosage & Forms
forms:
  - type: "capsule"
    typeLabel:
      en: "Capsule"
      zh: "胶囊"
      ja: "カプセル"
    releaseType: "immediate"
    releaseTypeLabel:
      en: "Immediate Release"
      zh: "速释"
      ja: "即放性"
    brandName: "Strattera"
    strengths: ["10mg", "18mg", "25mg", "40mg", "60mg", "80mg", "100mg"]
    durationHours: 24
    notes:
      en: "Once or twice daily dosing; do not open capsules"
      zh: "每日一次或两次给药；请勿打开胶囊"
      ja: "1日1回または2回投与；カプセルを開けないでください"

  - type: "liquid"
    typeLabel:
      en: "Oral Solution"
      zh: "口服溶液"
      ja: "内用液"
    releaseType: "immediate"
    releaseTypeLabel:
      en: "Immediate Release"
      zh: "速释"
      ja: "即放性"
    brandName: "Strattera"
    strengths: ["4mg/mL"]
    durationHours: 24
    notes:
      en: "Available in US and some markets for those who can't swallow capsules"
      zh: "适用于不能吞服胶囊者，在美国和部分市场有售"
      ja: "カプセルを飲み込めない方のために、米国および一部の市場で入手可能"

# Efficacy
onsetMinutes: null
peakEffectHours: 2
durationHours: 24

# Side Effects
sideEffects:
  common:
    - name:
        en: "nausea"
        zh: "恶心"
        ja: "悪心"
      frequency: "20-30%"
    - name:
        en: "decreased appetite"
        zh: "食欲下降"
        ja: "食欲減退"
      frequency: "15-25%"
    - name:
        en: "fatigue/somnolence"
        zh: "疲劳/嗜睡"
        ja: "疲労/傾眠"
      frequency: "10-20%"
    - name:
        en: "dry mouth"
        zh: "口干"
        ja: "口渇"
      frequency: "15-20%"
    - name:
        en: "headache"
        zh: "头痛"
        ja: "頭痛"
      frequency: "15-20%"
    - name:
        en: "abdominal pain"
        zh: "腹痛"
        ja: "腹痛"
      frequency: "10-20%"
    - name:
        en: "vomiting"
        zh: "呕吐"
        ja: "嘔吐"
      frequency: "10-15%"
    - name:
        en: "constipation"
        zh: "便秘"
        ja: "便秘"
      frequency: "10%"

  uncommon:
    - name:
        en: "dizziness"
        zh: "头晕"
        ja: "めまい"
      frequency: "5-10%"
    - name:
        en: "mood swings"
        zh: "情绪波动"
        ja: "気分変動"
      frequency: "5%"
    - name:
        en: "insomnia"
        zh: "失眠"
        ja: "不眠"
      frequency: "5%"
    - name:
        en: "erectile dysfunction (adults)"
        zh: "勃起功能障碍（成人）"
        ja: "勃起不全（成人）"
      frequency: "5-10%"
    - name:
        en: "urinary retention"
        zh: "尿潴留"
        ja: "尿閉"
      frequency: "5%"

  serious:
    - name:
        en: "suicidal ideation"
        zh: "自杀意念"
        ja: "自殺念慮"
      notes:
        en: "Black box warning; monitor closely, especially early in treatment"
        zh: "黑框警告；需密切监测，尤其是治疗初期"
        ja: "ブラックボックス警告；特に治療初期は注意深くモニタリングが必要"
    - name:
        en: "hepatotoxicity"
        zh: "肝毒性"
        ja: "肝毒性"
      notes:
        en: "Rare but serious; discontinue if jaundice or liver damage signs"
        zh: "罕见但严重；如出现黄疸或肝损伤迹象应停药"
        ja: "まれだが重篤；黄疸や肝障害の兆候があれば中止"
    - name:
        en: "severe allergic reactions"
        zh: "严重过敏反应"
        ja: "重度アレルギー反応"
      notes:
        en: "Angioedema, urticaria reported"
        zh: "有血管性水肿、荨麻疹报告"
        ja: "血管性浮腫、蕁麻疹の報告あり"
    - name:
        en: "cardiovascular effects"
        zh: "心血管影响"
        ja: "心血管への影響"
      notes:
        en: "Increased heart rate and blood pressure"
        zh: "心率和血压升高"
        ja: "心拍数と血圧の上昇"
    - name:
        en: "priapism"
        zh: "阴茎异常勃起"
        ja: "持続勃起症"
      notes:
        en: "Rare; requires immediate medical attention"
        zh: "罕见；需立即就医"
        ja: "まれ；直ちに医療処置が必要"

# Safety
contraindications:
  en:
    - "Hypersensitivity to atomoxetine"
    - "MAO inhibitor use within 14 days"
    - "Narrow-angle glaucoma"
    - "Pheochromocytoma"
    - "Severe cardiovascular disorders"
  zh:
    - "对托莫西汀过敏"
    - "14天内使用过MAO抑制剂"
    - "窄角型青光眼"
    - "嗜铬细胞瘤"
    - "严重心血管疾病"
  ja:
    - "アトモキセチンに対する過敏症"
    - "14日以内のMAO阻害剤使用"
    - "閉塞隅角緑内障"
    - "褐色細胞腫"
    - "重度の心血管疾患"

drugInteractions:
  - drug:
      en: "MAO inhibitors"
      zh: "MAO抑制剂"
      ja: "MAO阻害剤"
    severity: "major"
    effect:
      en: "Serious, potentially fatal reactions"
      zh: "严重的、可能致命的反应"
      ja: "重篤で致命的な可能性のある反応"
  - drug:
      en: "CYP2D6 inhibitors (fluoxetine, paroxetine)"
      zh: "CYP2D6抑制剂（氟西汀、帕罗西汀）"
      ja: "CYP2D6阻害剤（フルオキセチン、パロキセチン）"
    severity: "moderate"
    effect:
      en: "Increased atomoxetine levels"
      zh: "托莫西汀血药浓度升高"
      ja: "アトモキセチン濃度の上昇"
  - drug:
      en: "Albuterol (salbutamol)"
      zh: "沙丁胺醇"
      ja: "サルブタモール"
    severity: "moderate"
    effect:
      en: "Enhanced cardiovascular effects"
      zh: "心血管作用增强"
      ja: "心血管作用の増強"
  - drug:
      en: "Antihypertensives"
      zh: "降压药"
      ja: "降圧薬"
    severity: "moderate"
    effect:
      en: "May reduce effectiveness"
      zh: "可能降低疗效"
      ja: "効果を低下させる可能性"

blackBoxWarnings:
  en:
    - "Increased risk of suicidal ideation in children and adolescents; monitor closely"
  zh:
    - "儿童和青少年自杀意念风险增加；需密切监测"
  ja:
    - "小児および青年における自殺念慮のリスク増加；注意深くモニタリングが必要"

pregnancyCategory: "C"

foodInteractions:
  en: "Can be taken with or without food; food may reduce GI side effects"
  zh: "可随餐或空腹服用；进食可减少胃肠道副作用"
  ja: "食事の有無にかかわらず服用可能；食事により消化器系副作用が軽減される可能性"

# Practical Information
typicalDosing:
  children:
    startingDose: "0.5mg/kg/day"
    maxDose: "1.4mg/kg/day or 100mg/day"
    notes:
      en: "Increase to target of 1.2mg/kg/day after 1 week; full effect takes 4-6 weeks"
      zh: "1周后增加至目标剂量1.2mg/kg/天；完全起效需4-6周"
      ja: "1週間後に1.2mg/kg/日の目標用量に増量；完全な効果発現には4〜6週間"
  adults:
    startingDose: "40mg/day"
    maxDose: "100mg/day"
    notes:
      en: "Target dose 80mg/day; can be once daily or divided"
      zh: "目标剂量80mg/天；可每日一次或分次服用"
      ja: "目標用量80mg/日；1日1回または分割投与可能"

costEstimate:
  US:
    brand: "$350-400/month"
    generic: "$50-150/month"
  CN:
    brand: "¥400-800/month"
    generic: "¥200-400/month"

storageRequirements:
  en: "Room temperature (25°C), protect from moisture"
  zh: "室温保存（25°C），避免潮湿"
  ja: "室温（25°C）で保存、湿気を避ける"

# Approval & Availability
approvals:
  - region: "US"
    agency: "FDA"
    year: 2002
    approvedAges:
      en: "6 years and older"
      zh: "6岁及以上"
      ja: "6歳以上"
    indications:
      en: ["ADHD"]
      zh: ["注意缺陷多动障碍"]
      ja: ["ADHD"]
    available: true
    notes:
      en: "First non-stimulant approved for ADHD"
      zh: "首个获批用于ADHD的非兴奋剂药物"
      ja: "ADHDに承認された最初の非刺激薬"

  - region: "CN"
    agency: "NMPA"
    year: 2007
    approvedAges:
      en: "6 years and older"
      zh: "6岁及以上"
      ja: "6歳以上"
    indications:
      en: ["ADHD"]
      zh: ["注意缺陷多动障碍"]
      ja: ["ADHD"]
    available: true
    notes:
      en: "Brand capsules discontinued Jan 2024; oral solution and domestic generics available"
      zh: "品牌胶囊2024年1月停产；口服溶液和国产仿制药可用"
      ja: "ブランドカプセルは2024年1月に販売終了；経口液と国内ジェネリックが利用可能"

  - region: "EU"
    agency: "EMA"
    year: 2004
    approvedAges:
      en: "6 years and older"
      zh: "6岁及以上"
      ja: "6歳以上"
    indications:
      en: ["ADHD"]
      zh: ["注意缺陷多动障碍"]
      ja: ["ADHD"]
    available: true
    notes:
      en: "Approved for children and adults"
      zh: "适用于儿童和成人"
      ja: "小児および成人に承認"

  - region: "JP"
    agency: "PMDA"
    year: 2009
    approvedAges:
      en: "6 years and older"
      zh: "6岁及以上"
      ja: "6歳以上"
    indications:
      en: ["ADHD"]
      zh: ["注意缺陷多动障碍"]
      ja: ["ADHD"]
    available: true
    notes:
      en: "No registration requirement (unlike stimulants)"
      zh: "无需登记（与兴奋剂不同）"
      ja: "登録要件なし（刺激薬とは異なる）"

  - region: "UK"
    agency: "MHRA"
    year: 2004
    approvedAges:
      en: "6 years and older"
      zh: "6岁及以上"
      ja: "6歳以上"
    indications:
      en: ["ADHD"]
      zh: ["注意缺陷多动障碍"]
      ja: ["ADHD"]
    available: true
    notes:
      en: ""
      zh: ""
      ja: ""

  - region: "AU"
    agency: "TGA"
    year: 2007
    approvedAges:
      en: "6 years and older"
      zh: "6岁及以上"
      ja: "6歳以上"
    indications:
      en: ["ADHD"]
      zh: ["注意缺陷多动障碍"]
      ja: ["ADHD"]
    available: true
    notes:
      en: ""
      zh: ""
      ja: ""

  - region: "CA"
    agency: "Health Canada"
    year: 2004
    approvedAges:
      en: "6 years and older"
      zh: "6岁及以上"
      ja: "6歳以上"
    indications:
      en: ["ADHD"]
      zh: ["注意缺陷多动障碍"]
      ja: ["ADHD"]
    available: true
    notes:
      en: ""
      zh: ""
      ja: ""

# Special Considerations
specialConsiderations:
  cardiacRisk:
    en: "Can increase heart rate and blood pressure; use caution in cardiovascular disease"
    zh: "可升高心率和血压；心血管疾病患者需谨慎使用"
    ja: "心拍数と血圧を上昇させる可能性；心血管疾患には注意"
  abuseRisk:
    en: "No abuse potential; not a controlled substance"
    zh: "无滥用风险；非管制药物"
    ja: "乱用の可能性なし；規制物質ではない"
  withdrawalNotes:
    en: "No withdrawal symptoms; can be stopped without tapering"
    zh: "无戒断症状；可直接停药无需减量"
    ja: "離脱症状なし；漸減なしで中止可能"
  monitoringRequired:
    en: "Blood pressure, heart rate, liver function if symptoms; mood/suicidality in youth"
    zh: "血压、心率；如有症状监测肝功能；青少年需监测情绪/自杀倾向"
    ja: "血圧、心拍数、症状があれば肝機能；若年者では気分/自殺傾向"

# Travel Rules
travelRules:
  generalAdvice:
    en: "Atomoxetine is NOT a controlled substance, making international travel significantly easier than with stimulants. However, carry prescription documentation for customs."
    zh: "托莫西汀不是管制药物，国际旅行比兴奋剂容易得多。但仍建议携带处方文件以备海关检查。"
    ja: "アトモキセチンは規制物質ではないため、刺激薬よりも国際旅行がかなり容易です。ただし、税関用に処方書類を携帯してください。"

  requiredDocumentation:
    - type: "prescription"
      typeLabel:
        en: "Valid prescription"
        zh: "有效处方"
        ja: "有効な処方箋"
      notes:
        en: "Recommended but not strictly required in most countries"
        zh: "建议携带但大多数国家不严格要求"
        ja: "推奨されるが、ほとんどの国では厳密には必要ない"

  maxPersonalSupply:
    default: "90 days"

  crossBorderRules:
    - fromRegion: "US"
      toRegion: "JP"
      status: "allowed"
      statusLabel:
        en: "Allowed"
        zh: "允许"
        ja: "許可"
      requirements:
        en:
          - "Carry prescription copy"
          - "Keep in original packaging"
        zh:
          - "携带处方副本"
          - "保持原包装"
        ja:
          - "処方箋のコピーを携帯"
          - "元のパッケージを維持"
      maxSupply: "90 days"
      notes:
        en: "No special permit required. Atomoxetine is available in Japan and is not a controlled substance."
        zh: "无需特别许可。托莫西汀在日本可用且不是管制药物。"
        ja: "特別な許可は不要です。アトモキセチンは日本で入手可能で、規制物質ではありません。"

    - fromRegion: "US"
      toRegion: "CN"
      status: "allowed"
      statusLabel:
        en: "Allowed"
        zh: "允许"
        ja: "許可"
      requirements:
        en:
          - "Carry prescription copy"
          - "Keep in original packaging"
        zh:
          - "携带处方副本"
          - "保持原包装"
        ja:
          - "処方箋のコピーを携帯"
          - "元のパッケージを維持"
      maxSupply: "90 days"
      notes:
        en: "Atomoxetine is approved in China. No special import requirements for personal use."
        zh: "托莫西汀在中国已获批。个人使用无特殊进口要求。"
        ja: "アトモキセチンは中国で承認されています。個人使用に特別な輸入要件はありません。"

    - fromRegion: "US"
      toRegion: "EU"
      status: "allowed"
      statusLabel:
        en: "Allowed"
        zh: "允许"
        ja: "許可"
      requirements:
        en:
          - "Carry prescription copy"
          - "Keep in original packaging"
        zh:
          - "携带处方副本"
          - "保持原包装"
        ja:
          - "処方箋のコピーを携帯"
          - "元のパッケージを維持"
      maxSupply: "90 days"
      notes:
        en: "No special requirements for non-controlled medications. Atomoxetine is widely available in EU."
        zh: "非管制药物无特殊要求。托莫西汀在欧盟广泛可用。"
        ja: "非規制薬物には特別な要件はありません。アトモキセチンはEUで広く入手可能です。"

# Metadata
lastUpdated: 2025-12-02

sources:
  - "https://www.goodrx.com/conditions/adhd/non-stimulant-adhd-meds"
  - "https://zhuanlan.zhihu.com/p/702636281"
  - "https://www.gelonghui.com/p/713050"
  - "https://h-navi.jp/column/article/35028853"

notes:
  en: "First non-stimulant ADHD medication. Good option for those who can't tolerate stimulants or have substance abuse history. Takes 4-6 weeks for full effect (not immediate like stimulants). Eli Lilly discontinued capsule supply to China in Jan 2024 but domestic generics available."
  zh: "首个非兴奋剂ADHD药物。适合不能耐受兴奋剂或有药物滥用史的患者。完全起效需4-6周（不像兴奋剂那样立即起效）。礼来于2024年1月停止向中国供应胶囊剂型，但国产仿制药可用。"
  ja: "最初の非刺激性ADHD薬。刺激薬に耐えられない人や薬物乱用歴のある人に適しています。完全な効果発現には4〜6週間かかります（刺激薬のような即効性はありません）。イーライリリーは2024年1月に中国へのカプセル供給を終了しましたが、国内ジェネリックは入手可能です。"
